'No cognitive-enhancing effect of GLP-1 receptor agonism in antipsychotic-treated, obese patients with schizophrenia': authors' response

Acta Psychiatr Scand. 2017 Nov;136(5):526-527. doi: 10.1111/acps.12795. Epub 2017 Aug 28.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Antipsychotic Agents*
  • Glucagon-Like Peptide-1 Receptor*
  • Humans
  • Obesity
  • Schizophrenia

Substances

  • Antipsychotic Agents
  • Glucagon-Like Peptide-1 Receptor